Blaine Oswald
Family · Leavenworth, KSNPI 1285235341
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $11,641 of the $19,268 with a category attached, or 60.4%. 20 manufacturers reported payments, led by Otsuka America Pharmaceutical, Inc. at 55.0% of the total. Among family clinicians in KS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 435 payments — averaging $44.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$11K
- AbbVie$4K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$1K
- Alkermes, Inc.$867
- Teva Pharmaceuticals USA, Inc.$852
- Vanda Pharmaceuticals Inc.$577
- plus $2K from 14 others
What the payments were for
- Consulting fees$1,2757%
- Speaking & faculty fees$11,64160%
- Travel & lodging$7434%
- Food & beverage$5,49829%
- Education$1111%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 104 | $10,597 |
| AbbVie | 80 | $3,629 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 4 | $1,230 |
| Alkermes, Inc. | 59 | $867 |
| Teva Pharmaceuticals USA, Inc. | 66 | $852 |
| Vanda Pharmaceuticals Inc. | 37 | $577 |
| Lundbeck LLC | 22 | $282 |
| Johnson & Johnson | 11 | $274 |
| E.r. Squibb & Sons, L.L.C. | 12 | $195 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 8 | $133 |
| Janssen Scientific Affairs, LLC | 1 | $115 |
| Sunovion Pharmaceuticals Inc. | 6 | $106 |
| Neurocrine Biosciences, Inc. | 6 | $102 |
| Axsome Therapeutics, Inc. | 6 | $95 |
| Supernus Pharmaceuticals, Inc. | 3 | $52 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
| Almatica Pharma LLC | 2 | $34 |
| Indivior Inc. | 2 | $33 |
| Eisai Inc. | 2 | $29 |
| Tris Pharma Inc | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ABILIFY MAINTENA$9,247
- ABILIFY ASIMTUFII$8,603
- VRAYLAR$2,750
- REJOYN$1,160
- SPRAVATO$115
How this compares
$19,268 in reported general payments places this provider in the 95th percentile of 1,579 family providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 25 | $88,156 |
| RexultiBrexpiprazole | 39 | $58,662 |
| Abilify MaintenaAripiprazole | 17 | $53,256 |
| AuvelityDextromethorphan Hbr/Bupropion | 38 | $34,254 |
| VraylarCariprazine Hcl | 24 | $30,774 |
| ZyprexaOlanzapine | 24 | $26,064 |
| SpravatoEsketamine Hcl | 29 | $25,955 |
| CaplytaLumateperone Tosylate | 14 | $23,400 |
| Lurasidone Hcl | 19 | $4,116 |
| Oxcarbazepine | 62 | $3,388 |
| Buspirone Hcl | 152 | $3,178 |
| Chlorpromazine Hcl | 11 | $2,747 |
| Ziprasidone Hcl | 32 | $2,413 |
| Clozapine | 30 | $2,178 |
| Duloxetine Hcl | 91 | $1,888 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Spravato | $274 | $114,11154 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $10,597 | $111,91856 claims |
| Axsome Therapeutics, Inc.Auvelity | $95 | $34,25438 claims |
| AbbVieVraylar | $3,629 | $30,77424 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $133 | $23,40014 claims |
| Almatica Pharma LLCSertraline Hcl | $34 | $47724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,579 family providers in Kansas.
Other family in Leavenworth
- Zohra HussainiKansas City$329K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
- Kayla del RioWichita$147K
- Kelli RiceWichita$114K
- Tatum TolandTopeka$108K
- Mary GonzalesWichita$87K
- Erin FeitzOverland Park$36K
- Adam CaseKansas City$34K
- Jaimie HeldstabWestwood$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.